The Science Behind EBIOCAT™
Multi-Enzyme Biocatalysis, Engineered for Maximum Absorption
EBIOCAT™ is not a single enzyme — it is a precisely orchestrated cascade of complementary biocatalysts that work in concert to break down molecular barriers, enhance solubility, and unlock the full bioavailability of active ingredients.
The Challenge
The Bioavailability Problem
Up to 90% of new pharmaceutical compounds and a significant proportion of nutraceutical actives suffer from poor bioavailability — meaning the body absorbs only a fraction of the dose delivered. This is not a formulation failure. It is a fundamental biochemical challenge rooted in molecular structure, gut physiology, and the limitations of single-enzyme approaches.
Conventional enhancement strategies — cyclodextrins, nanoparticles, lipid systems — address solubility in isolation. They do not replicate the complexity of natural digestive biochemistry. EBIOCAT™ does.
of new drug compounds have poor bioavailability
average absorption loss in standard nutraceutical delivery
average bioavailability uplift with EBIOCAT™ platform
How It Works
The Enzyme Cascade Mechanism
EBIOCAT™ deploys a coordinated multi-enzyme system that mirrors and amplifies the body's own digestive biochemistry — operating across multiple molecular targets simultaneously.
Substrate Recognition
Proprietary enzyme blends identify and bind to specific molecular structures within the active ingredient matrix, initiating targeted catalytic activity at the substrate surface.
Structural Deconstruction
Complementary hydrolases and oxidoreductases work in sequence to cleave molecular bonds, reduce particle size, and expose hydrophilic binding sites — dramatically increasing surface area for absorption.
Solubility Enhancement
Modified molecular fragments exhibit significantly improved aqueous solubility. The cascade produces metabolite profiles optimized for intestinal epithelial uptake and systemic circulation.
Absorption Amplification
Enhanced solubility and reduced particle size combine to maximize passive diffusion and active transport across the intestinal barrier — delivering more active compound to systemic circulation.
Platform Design
Platform Architecture
EBIOCAT™ is engineered as a modular, substrate-adaptive platform — not a fixed formulation. Each deployment is calibrated to the specific active ingredient, delivery matrix, and target bioavailability profile.
Substrate Specificity
Enzyme selection and ratios are optimized per active ingredient class — polyphenols, terpenoids, alkaloids, peptides, and lipophilic compounds each require distinct catalytic profiles.
pH & Temperature Stability
Enzyme formulations are stabilized across the physiological pH range (2.0–8.0) and processing temperatures up to 65°C, ensuring activity through manufacturing and gastrointestinal transit.
Matrix Compatibility
EBIOCAT™ is compatible with capsule, tablet, powder, liquid, and functional food matrices — enabling seamless integration into existing manufacturing workflows without capital investment.
Dose Efficiency
By maximizing absorption per unit dose, EBIOCAT™ enables manufacturers to achieve equivalent or superior clinical outcomes at reduced active ingredient loads — improving cost-efficiency and tolerability.
Regulatory Alignment
All enzyme components are sourced from GRAS-affirmed or EU-approved organisms. The platform is designed for compliance with FDA, EFSA, and major international regulatory frameworks.
Scalable Manufacturing
Enzyme production is scalable from pilot to commercial volumes. EBIOCAT™ integrates into standard GMP manufacturing environments with minimal process modification.
Competitive Landscape
EBIOCAT™ vs. Conventional Enhancement Technologies
Ready to Explore the Science for Your Formulation?
Our scientific team works directly with formulators and R&D leads to evaluate EBIOCAT™ compatibility with your active ingredients and delivery systems.